Tags

Type your tag names separated by a space and hit enter

Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial.
Menopause. 2007 Sep-Oct; 14(5):866-74.M

Abstract

OBJECTIVE

Equol is more biologically active than its precursor daidzein, which is the principal isoflavone found in soybean. There are interindividual differences in the ability to produce equol; these may lead to differences in the effects of isoflavone intervention on human health. This study aimed to investigate whether the effects of soy isoflavones on bone and fat mass are related to an individual's equol status.

DESIGN

We performed a 1-year double-blind, randomized trial to compare the effects of isoflavone (75 mg of isoflavone conjugates/day) with those of placebo on bone mineral density, fat mass, and serum isoflavone concentrations in early postmenopausal Japanese women who were classified based on their equol-producer phenotype.

RESULTS

After 1 year, the isoflavone intervention significantly increased the serum equol concentration in the equol producers but not in the nonproducers. In the isoflavone group, the annualized changes in the bone mineral density of the total hip and intertrochanteric regions were -0.46% and -0.04%, respectively, in the equol producers and -2.28% and -2.61%, respectively, in the nonproducers; these values were significantly different (P<0.05 for both the regions). Significant differences were observed between the equol producers and nonproducers in the isoflavone group with regard to the annualized changes in the fat mass. No significant difference in the annualized changes in bone mineral density and fat mass was observed between the equol producers and nonproducers in the placebo group.

CONCLUSIONS

Our data suggest that the preventive effects of isoflavones on bone loss and fat accumulation in early postmenopausal women depend on an individual's equol-producing capacity.

Authors+Show Affiliations

Nutritional Epidemiology Program, National Institute of Health and Nutrition, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17464237

Citation

Wu, Jian, et al. "Possible Role of Equol Status in the Effects of Isoflavone On Bone and Fat Mass in Postmenopausal Japanese Women: a Double-blind, Randomized, Controlled Trial." Menopause (New York, N.Y.), vol. 14, no. 5, 2007, pp. 866-74.
Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause. 2007;14(5):866-74.
Wu, J., Oka, J., Ezaki, J., Ohtomo, T., Ueno, T., Uchiyama, S., Toda, T., Uehara, M., & Ishimi, Y. (2007). Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause (New York, N.Y.), 14(5), 866-74.
Wu J, et al. Possible Role of Equol Status in the Effects of Isoflavone On Bone and Fat Mass in Postmenopausal Japanese Women: a Double-blind, Randomized, Controlled Trial. Menopause. 2007 Sep-Oct;14(5):866-74. PubMed PMID: 17464237.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. AU - Wu,Jian, AU - Oka,Jun, AU - Ezaki,Junko, AU - Ohtomo,Takuya, AU - Ueno,Tomomi, AU - Uchiyama,Shigeto, AU - Toda,Toshiya, AU - Uehara,Mariko, AU - Ishimi,Yoshiko, PY - 2007/4/28/pubmed PY - 2007/12/19/medline PY - 2007/4/28/entrez SP - 866 EP - 74 JF - Menopause (New York, N.Y.) JO - Menopause VL - 14 IS - 5 N2 - OBJECTIVE: Equol is more biologically active than its precursor daidzein, which is the principal isoflavone found in soybean. There are interindividual differences in the ability to produce equol; these may lead to differences in the effects of isoflavone intervention on human health. This study aimed to investigate whether the effects of soy isoflavones on bone and fat mass are related to an individual's equol status. DESIGN: We performed a 1-year double-blind, randomized trial to compare the effects of isoflavone (75 mg of isoflavone conjugates/day) with those of placebo on bone mineral density, fat mass, and serum isoflavone concentrations in early postmenopausal Japanese women who were classified based on their equol-producer phenotype. RESULTS: After 1 year, the isoflavone intervention significantly increased the serum equol concentration in the equol producers but not in the nonproducers. In the isoflavone group, the annualized changes in the bone mineral density of the total hip and intertrochanteric regions were -0.46% and -0.04%, respectively, in the equol producers and -2.28% and -2.61%, respectively, in the nonproducers; these values were significantly different (P<0.05 for both the regions). Significant differences were observed between the equol producers and nonproducers in the isoflavone group with regard to the annualized changes in the fat mass. No significant difference in the annualized changes in bone mineral density and fat mass was observed between the equol producers and nonproducers in the placebo group. CONCLUSIONS: Our data suggest that the preventive effects of isoflavones on bone loss and fat accumulation in early postmenopausal women depend on an individual's equol-producing capacity. SN - 1072-3714 UR - https://www.unboundmedicine.com/medline/citation/17464237/Possible_role_of_equol_status_in_the_effects_of_isoflavone_on_bone_and_fat_mass_in_postmenopausal_Japanese_women:_a_double_blind_randomized_controlled_trial_ L2 - http://dx.doi.org/10.1097/gme.0b013e3180305299 DB - PRIME DP - Unbound Medicine ER -